Over the past 10 months, several high-profile stock splits helped animate an already lively stock market. One of them was that of the medical device expert DexCom (NASDAQ: DXCM), which completed a 4-for-1 stock split in June.
Of course, stock splits don’t fundamentally change the prospects of the company, and DexCom’s did little to jolt its stock performance in 2022. The company’s shares have performed more or less on par with the struggling stock market this year.
Can the healthcare company rebound in 2023? Let’s look closer at what DexCom has going on to find out.
Rolling out new devices
DexCom focuses on developing continuous glucose monitoring (CGM) devices, which allow diabetes patients to…